Cabaletta Bio to Participate in Guggenheim’s SMID Cap Biotech Conference
Rhea-AI Summary
Cabaletta Bio (Nasdaq: CABA), a clinical-stage biotechnology company specializing in curative targeted cell therapies for autoimmune diseases, has announced its upcoming participation in Guggenheim's SMID Cap Biotech Conference. The company will engage in a fireside chat scheduled for Wednesday, February 5, 2025, at 10:30 a.m. ET in New York, NY.
Interested parties can access a live webcast of the presentation through the News and Events section of Cabaletta Bio's website. The presentation recording will remain available for replay on the company's website for 30 days following the event.
Positive
- None.
Negative
- None.
News Market Reaction
On the day this news was published, CABA declined 1.25%, reflecting a mild negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
PHILADELPHIA, Jan. 29, 2025 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapies designed specifically for patients with autoimmune diseases, today announced that the Company will participate in a fireside chat at Guggenheim’s SMID Cap Biotech Conference on Wednesday, February 5, 2025, at 10:30 a.m. ET in New York, NY.
A live webcast of the presentation will be available on the News and Events section of the Company’s website at www.cabalettabio.com. Replays will be available on the website for 30 days.
About Cabaletta Bio
Cabaletta Bio (Nasdaq: CABA) is a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapies designed specifically for patients with autoimmune diseases. The CABA™ platform encompasses two complementary strategies which aim to advance the discovery and development of engineered T cell therapies with the potential to become deep and durable, perhaps curative, treatments for a broad range of autoimmune diseases. The lead CARTA (Chimeric Antigen Receptor T cells for Autoimmunity) strategy is prioritizing the development of rese-cel, a 4-1BB-containing fully human CD19-CAR T cell investigational therapy. Rese-cel is currently being evaluated in the RESET™ (REstoring SElf-Tolerance) clinical development program spanning multiple therapeutic areas, including rheumatology, neurology and dermatology. Cabaletta Bio’s headquarters and labs are located in Philadelphia, PA. For more information, please visit www.cabalettabio.com and connect with us on LinkedIn.
Contacts:
Anup Marda
Chief Financial Officer
investors@cabalettabio.com
William Gramig
Precision AQ
william.gramig@precisionaq.com
FAQ
When is Cabaletta Bio (CABA) presenting at Guggenheim's SMID Cap Biotech Conference 2025?
How can investors watch Cabaletta Bio's (CABA) Guggenheim Conference presentation?
How long will Cabaletta Bio's (CABA) Guggenheim Conference presentation be available for replay?
What type of therapies is Cabaletta Bio (CABA) developing?
